SEC Form 4 · accession 0001652956-26-000018
Guardant Health, Inc. · GH
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Terilyn J. Monroe
Officer — Chief People Officer
Period of report
Aug 12, 2026
Accepted (ET)
Aug 13, 2026 · 7:21 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001576280
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 12, 2026 | M | 32,288 | $20.14 | A | 55,267 | D | |
| Common Stock | Aug 12, 2026 | M | 14,012 | $28.61 | A | 69,279 | D | |
| Common StockF1 | Aug 12, 2026 | S | 3,704 | $163.4141 | D | 65,575 | D | |
| Common StockF2 | Aug 12, 2026 | S | 9,934 | $164.2712 | D | 55,641 | D | |
| Common StockF3 | Aug 12, 2026 | S | 19,014 | $165.1578 | D | 36,627 | D | |
| Common StockF4 | Aug 12, 2026 | S | 13,248 | $166.1069 | D | 23,379 | D | |
| Common StockF5 | Aug 12, 2026 | S | 400 | $167.9188 | D | 22,979 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $20.14 | Aug 12, 2026 | M | 32,288 | D | — | Feb 26, 2034 | Common Stock | 32,288 | 10,916 | D |
| Stock Option (Right to Buy)F7 | $28.61 | Aug 12, 2026 | M | 14,012 | D | — | Nov 8, 2034 | Common Stock | 14,012 | 18,615 | D |
Explanation of responses
- F1Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $162.80 to $163.78. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $163.81 to $164.805. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F3Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $164.825 to $165.82. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F4Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $165.85 to $166.825. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F5Represents the weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $167.695 to $168.02. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
- F6This represents a stock option award granted on February 26, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 2, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.
- F7This represents a stock option award granted on November 8, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on October 1, 2025 and the remaining 67% of the shares vests in equal monthly installments over the remaining two-year period thereafter.